- "Let's all have a little patience," says Pfizer (NYSE:PFE) CEO Albert Bourla, speaking on the earnings conference call. It's an interesting choice of words considering Bourla made the press rounds one month ago kind of setting expectations for some news on the company's Covid-19 vaccine trial by the end of October.
- "I wish an analyst would bring this up," tweets Brad Loncar. "Clinical trial guidance slippage is almost always meaningful."
- Bourla further notes the data monitoring committee has not yet been unblinded to data, and that any announcement would come about a week after that group looks at it - that likely means we're into November before getting any news. He remains "cautiously optimistic" that the vaccine will work.
- See page seven of the earnings call presentation. More than 42K participants have been enrolled in the trial, with nearly 36K having received a 2nd dose as of October 26.
- https://seekingalpha.com/news/3626485-no-interim-analysis-on-covidminus-19-vaccine-candidate-pfizer-conference-call
Tuesday, October 27, 2020
No interim analysis on Covid-19 vaccine candidate - Pfizer conference call
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.